ANGPTL4 and coronary artery disorder: Further study showed that carriers of inactivating genetic variants of ANGPTL4 had lower triglyceride [66] levels and CAD risk, suggesting that ANGPTL4 might be a possible therapeutic target for the treatment of ischemic heart disease [67].